The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. - Wikidata - awgldk - TriplyDB

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

http://www.wikidata.org/entity/Q34216710

about

How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion Pharmacogenomics of hypertension and heart disease Use of contemporary genetics in cardiovascular diagnosis Advantages of Array-Based Technologies for Pre-Emptive Pharmacogenomics Testing Pharmacogenomics of statins: understanding susceptibility to adverse effects Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics Statin intolerance - a question of definition.Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.Candidate-Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol-Lowering Response to Simvastatin Pharmacogenetic testing through the direct-to-consumer genetic testing company 23andMe.State of Art of Cancer Pharmacogenomics in Latin American Populations.Is there a clinically relevant interaction between clarithromycin and statins not metabolized by cytochrome P450 3A4?Pharmacogenomics in cardiology--genetics and drug response: 10 years of progress.From a fish tank injury to hospital haemodialysis: the serious consequences of drug interactions.Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril)-Induced Cough: a Pharmacogenetic Study.Genotype-based clinical trials in cardiovascular disease.SLCO1B1 genetic variants, long-term low-density lipoprotein cholesterol levels and clinical events in patients following cardiac catheterization.Hypertension pharmacogenomics: in search of personalized treatment approaches Cardiovascular Pharmacogenomics--Implications for Patients With CKD.The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia.Assessing the capability of massively parallel sequencing for opportunistic pharmacogenetic screening.Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations.Statin intolerance: diagnosis and remedies.Ezetimibe plus simvastatin for the treatment of hypercholesterolemia.Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders.Safety considerations with fenofibrate/simvastatin combination.Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Personalized medicine: Genetic risk prediction of drug response.Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC).Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1).The Application of Genomics in Diabetes: Barriers to Discovery and Implementation.Evidence and resources to implement pharmacogenetic knowledge for precision medicine.Integrating pharmacogenomics into electronic health records with clinical decision support.Genome-wide common and rare variant analysis provides novel insights into clozapine-associated neutropenia.

P2860

Q24273350-4C9FF5E7-1945-4362-8ECC-6E3764743633 Q27015722-2228F809-CB3A-4380-85C7-C47FEABE41F5 Q27025306-747D482D-6A4C-4F89-93FE-D991C8D0A64C Q28079766-33F21DFE-C36C-458A-ADB5-60D81EF6375E Q28079822-D952C206-0E91-46EF-BDD4-9804A64A98DE Q28552832-32069A3D-11E5-4B71-BEC1-03C2EEB5ABC1 Q28554199-19DAD116-8989-4A5F-B7AC-6AEE495E013E Q30245218-7608B334-B7BC-4FAA-8AF2-356228D2B880 Q31058146-F05771D1-CC19-4A82-899D-6279E08A138B Q33648028-F047C177-2A9D-4056-8BB2-2761A5E7DDD9 Q33815409-DE72BDFA-61A2-4015-A236-F9A94587B2F4 Q33838298-BB0CC1C9-5C47-4467-890D-5E803E887F46 Q35088411-F7C7B224-8F5F-4184-AA9B-11453415062F Q35769279-E6360AEE-E466-4953-B2A4-6EFD178DB6DD Q35779291-C5A444CD-E805-4FEB-93F8-0E8DC5C1D8F3 Q36256049-8A73941E-1471-425D-8B83-85FAE76A70AA Q36321069-E282DDBE-F95E-4EC0-9A89-12E2816103EA Q36393911-3A0086AB-16FF-41ED-B504-5E4AC98BF484 Q36480609-38A5E942-5FA7-434C-9545-E354B8A95C78 Q36652960-4F30275D-40BC-4E6F-9C8F-3415E5781363 Q36696635-971FF6CE-AC24-46B8-98B1-908B28A722F0 Q36956524-5DE3DF06-D399-4D91-844F-4A319D555B37 Q37651303-101C51EB-5832-4395-B1A2-3CF258EDBB9C Q37745681-071651C9-ADE5-4249-AD17-5AC87EB40535 Q38430744-9E2F7853-5671-4DB3-99F1-FCB1B70ED9D7 Q38446859-0ACBBF18-D6EF-40C6-B179-A761B43ACD04 Q38510741-FDE2B093-A30F-42C2-9085-BFBF527314D9 Q38541832-F71F9394-D040-42EB-A15E-2AA104BF6925 Q38663481-5715707C-8967-42DC-A99C-520E2B0503EE Q38707185-24AE93FA-978E-4A74-B8AF-2132FD2BA75F Q38737633-B61E3566-BB81-4AF2-9EB7-F73580407145 Q38756015-CAED2917-9617-4A36-B9CF-A2BAE9E0F40F Q38798449-807EEEB5-59E2-4EBD-9903-9A684A50DC83 Q38888369-866C6F27-C6C3-469E-944D-BE534EF67DEC Q38888585-56D22FD0-7A4E-4E93-820C-94FF565B3B90 Q39034284-D33198E8-1B63-4584-950A-2B0B650F2C41 Q39123582-CF699BAB-1A25-4280-A6C1-C93D969518E6 Q39173298-28FFF7DC-3D03-4712-8C93-F2CCFB6F5935 Q39173300-0F438B12-D380-4FA0-920C-6B55972417F4 Q39613623-CA537E6A-1F4C-422D-A895-427BF8F4BD61

P2860

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.

http://www.wikidata.org/entity/Q34216710

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@ast

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@en

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@nl

type

label

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@ast

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@en

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@nl

prefLabel

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@ast

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@en

The clinical pharmacogenetics ...... induced myopathy: 2014 update.

@nl

P1433

Q34216710-8E7926B0-1FD4-4035-8618-01A7F1183826

P1476

Q34216710-ED3B0A81-FEDE-4DAD-A481-9CA2548B3B5E

P2093

Q34216710-0238303F-77D2-4326-93AB-F03656DC4026

Q34216710-05ACDD49-085C-4EBD-A76C-1FB488DB2163

Q34216710-4DE6EEC9-C23F-4C95-9898-2D9BD078E7F4

Q34216710-75DAF3DD-6214-4BD9-A75C-BBEBAFD0A905

Q34216710-92FB306A-4082-45DF-B03B-37ADDDFA5A25

Q34216710-A80B1CD9-6962-4553-A74F-BCAEF4A084CD

Q34216710-B09A31F7-999B-40EA-BA9E-6EA3DA18F1DC

Q34216710-B4091330-1AB6-4579-BFC2-A1A17C563455

Q34216710-D35FDB77-1CE0-4CBF-B421-AD33A4DB9BD2

Q34216710-D3F96CB8-C80F-49B0-8757-17B4BDEEAABF

P2860

Q34216710-03130FEF-85E7-47D9-BBAE-AE2C5B65AB28

Q34216710-0E781BF1-0A96-4583-9C30-CF17866771BE

Q34216710-1B4E6F19-666E-479F-82B8-DEFE2028D3E4

Q34216710-1B51D7E6-BD97-45C6-BBA5-DB9E4B8B646B

Q34216710-1FDCA90A-BB91-4E07-9BAF-C31A3D1F6F82

Q34216710-208B221F-7104-40DD-889C-5B19A7DE23B4

Q34216710-233A53E1-24F9-4B15-8D29-C07ACA2D5343

Q34216710-2448BFE7-E859-4777-820B-4D02BEDB7C74

Q34216710-2A132A19-6B34-40A0-A82E-2A273511A196

Q34216710-2E863216-788C-4D65-9818-15E8F6FCAA19

P304

Q34216710-F88E5D38-47BB-4F81-85B3-CE0E5B88A188

P31

Q34216710-7B3524F7-0FF5-4090-A3E3-F7016F8AD1A7

P356

Q34216710-1D1EFE03-0772-4531-9D2A-C212530A1DE6

P407

Q34216710-3B8824A5-1DAC-4F0E-AF51-13911F019734

P433

Q34216710-577CAB7D-7D72-45DC-8780-08DCEF8729B5

P478

Q34216710-6E1D9EDD-21D4-4C53-87A5-315EA85BC4FA

P50

Q34216710-55112065-A118-4CD9-8FD0-E2009BF848F2

Q34216710-5563073C-4AEF-4BC2-A9A3-415A4AA6D2BD

Q34216710-D573B3CC-6F67-448C-B7C3-FF968F6A18D6

P577

Q34216710-D7091ECD-5FB7-448A-BE22-9D95D3D6324F

P698

Q34216710-148A2446-841E-44D7-B827-0DB6F549DE65

P932

Q34216710-0FC8D78A-B299-4D13-9EC3-152CDD3A8CAB

P356

P1433

Clinical Pharmacology & Therapeutics

P1476

The clinical pharmacogenetics ...... -induced myopathy: 2014 update

@en

P2093

C E Haidar

http://www.w3.org/2001/XMLSchema#string

D M Roden

http://www.w3.org/2001/XMLSchema#string

D Voora

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

K E Caudle

http://www.w3.org/2001/XMLSchema#string

L Gong

http://www.w3.org/2001/XMLSchema#string

Q Feng

http://www.w3.org/2001/XMLSchema#string

R A Wilke

http://www.w3.org/2001/XMLSchema#string

R M Cooper-DeHoff

http://www.w3.org/2001/XMLSchema#string

R M Krauss

http://www.w3.org/2001/XMLSchema#string

P2860

SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink

Leveraging the electronic health record to implement genomic medicine

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

SLCO1B1 variants and statin-induced myopathy--a genomewide study

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Statin-associated myopathy.

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.

P304

423-428

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CLPT.2014.125

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24918167

http://www.w3.org/2001/XMLSchema#string

P932

4169720

http://www.w3.org/2001/XMLSchema#string